Callahan Advisors LLC Acquires 87,203 Shares of Pfizer Inc. (NYSE:PFE)

Callahan Advisors LLC lifted its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 17.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 575,497 shares of the biopharmaceutical company's stock after acquiring an additional 87,203 shares during the quarter. Pfizer accounts for about 1.4% of Callahan Advisors LLC's holdings, making the stock its 24th biggest position. Callahan Advisors LLC's holdings in Pfizer were worth $14,583,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of PFE. Cromwell Holdings LLC increased its holdings in Pfizer by 64.3% in the 1st quarter. Cromwell Holdings LLC now owns 18,533 shares of the biopharmaceutical company's stock valued at $470,000 after purchasing an additional 7,250 shares in the last quarter. SteelPeak Wealth LLC increased its stake in shares of Pfizer by 1,101.3% in the first quarter. SteelPeak Wealth LLC now owns 221,061 shares of the biopharmaceutical company's stock valued at $5,602,000 after purchasing an additional 202,659 shares during the period. Diversify Wealth Management LLC increased its stake in shares of Pfizer by 6.6% in the first quarter. Diversify Wealth Management LLC now owns 11,460 shares of the biopharmaceutical company's stock valued at $273,000 after purchasing an additional 710 shares during the period. Xponance Inc. increased its stake in shares of Pfizer by 0.4% during the first quarter. Xponance Inc. now owns 854,869 shares of the biopharmaceutical company's stock valued at $21,662,000 after acquiring an additional 3,621 shares during the period. Finally, Croban acquired a new position in shares of Pfizer during the first quarter valued at approximately $715,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Price Performance

NYSE:PFE traded down $0.13 during trading hours on Friday, hitting $25.65. The stock had a trading volume of 34,838,317 shares, compared to its average volume of 41,793,724. The company has a 50 day simple moving average of $23.86 and a two-hundred day simple moving average of $24.81. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The firm has a market capitalization of $145.83 billion, a price-to-earnings ratio of 18.59, a P/E/G ratio of 0.94 and a beta of 0.58.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The company had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. During the same period in the previous year, the firm posted $0.82 EPS. The firm's revenue was down 7.8% compared to the same quarter last year. Research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.71%. The ex-dividend date is Friday, July 25th. Pfizer's payout ratio is 124.64%.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. BMO Capital Markets decreased their price target on shares of Pfizer from $36.00 to $30.00 in a research report on Thursday, April 17th. Citigroup lifted their price objective on Pfizer from $23.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. HSBC cut their target price on Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a report on Monday, May 19th. Morgan Stanley raised their target price on Pfizer from $31.00 to $32.00 and gave the company an "equal weight" rating in a report on Wednesday, April 30th. Finally, TD Cowen dropped their price objective on Pfizer from $32.00 to $28.00 and set a "hold" rating on the stock in a research note on Tuesday, April 22nd. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have given a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $28.55.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.